Holen Sie sich die Stockscreener-App
85.15
0.05%
-0.04
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$85.19
Offen:
$85.52
24-Stunden-Volumen:
2.40M
Relative Volume:
0.63
Marktkapitalisierung:
$49.08B
Einnahmen:
$6.30B
Nettoeinkommen (Verlust:
$1.07B
KGV:
46.26
EPS:
1.8406
Netto-Cashflow:
$1.09B
1W Leistung:
-1.32%
1M Leistung:
-6.24%
6M Leistung:
+5.06%
1J Leistung:
+11.09%
1-Tages-Spanne:
$84.66
$86.48
1-Wochen-Bereich:
$84.48
$88.19
52-Wochen-Spanne:
$72.30
$96.29
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, MDT, SYK, BSX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
97.50 | 168.71B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-01 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients - Yahoo Finance
Edwards Lifesciences stock up 726% in 15 years, beating market - scanx.trade
Why Are Traders Reassessing Edwards Lifesciences (NYSE:EW)? - Kalkine Media
EW News | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
ETFs Investing in Edwards Lifesciences Corporation Stocks - TradingView
US28176EAD0 Bond Profile: Coupon and Redemption - TradingView
Edwards Lifesciences Corporation (NYSE:EW) Stock Has Average Target Price of $100.27 - MarketBeat
Wall Street Zen Downgrades Edwards Lifesciences (NYSE:EW) to Hold - MarketBeat
Edwards Lifesciences (EW) Stock Forecast and Price Target 2026 $EW - MarketBeat
Claim your share of the $39 million Edwards Lifesciences securities class action settlement - Claim Depot
For Edwards Lifesciences, Singapore is integral to its global supply chain strategy - Singapore Economic Development Board (EDB)
EW IMPORTANT DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important December 13 Deadline in Securities Class ActionEW - TMX Newsfile
Andra AP fonden Boosts Stake in Edwards Lifesciences Corporation $EW - MarketBeat
How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions - Yahoo Finance
Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion - Yahoo Finance
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead - Yahoo Finance
Edwards Lifesciences stock heads into the open after a 4.1 percent jump - AD HOC NEWS
Is It Too Late to Buy Edwards Lifesciences Corp (EW) After 4.1% Rally? GF Value Says Undervalued - GuruFocus
Edwards Lifesciences Corporation's Stock Price Soars to $89.28, Marking a Strong 4.13% Increase - Smartkarma
Edwards Lifesciences at deutsche bank 2026 healthcare summit: broader growth - Investing.com
Bank of America Corp DE Takes $605.40 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences stock heads into the open after a mid-80 dollar close - AD HOC NEWS
California State Teachers Retirement System Buys 23,304 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
$100 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth This Much Today - Benzinga
Edwards Lifesciences Corp (EW) Stock Analysis: A Potential 19.67% Upside in the Healthcare Sector - DirectorsTalk Interviews
Stock Traders Purchase Large Volume of Edwards Lifesciences Call Options (NYSE:EW) - MarketBeat
Truist raises Edwards Lifesciences target to $95 - scanx.trade
Wall Street Zen Upgrades Edwards Lifesciences (NYSE:EW) to "Buy" - MarketBeat
Insider Daniel Lippis Sells 619 Shares of Edwards Lifesciences C - GuruFocus
Edwards Lifesciences CVP Daniel Lippis sells $54,168 in stock By Investing.com - Investing.com Australia
Why Edwards Lifesciences (EW) Stock Is Down Today - Quiver Quantitative
Edwards Lifesciences, Medtronic score CMS win for TAVR - MassDevice
CMS TAVR changes, a boon for Edwards - BioWorld News
Edwards Lifesciences stock price target maintained at $85 by Canaccord - Investing.com Canada
Engineers Gate Manager LP Sells 81,590 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Comments on TAVR National Coverage Decision - Finviz
Edwards Lifesciences maintains 2026 guidance after CMS TAVR NCD - scanx.trade
Edwards Lifesciences stock edges higher after raised 2026 revenue guidance - ad-hoc-news.de
Edwards Lifesciences stock heads into the open after a mild decline - ad-hoc-news.de
EW Stock Quote Price and Forecast - CNN
Can Edwards Lifesciences (NYSE:EW) Withstand Market Pressure? - Kalkine Media
Amundi Decreases Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences stock heads into the open after a 3.2 percent drop - ad-hoc-news.de
Edwards Lifesciences Corp (EW) Stock Down 3.5% -- Now Undervalued? GF Score: 95/100 - GuruFocus
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Is Edwards Lifesciences Stock Underperforming the Dow? - Yahoo Finance
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases New Shares in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound (NYSE:EW) - Seeking Alpha
Azimuth Capital Investment Management LLC Decreases Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.46%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):